Atricure Inc. Stock
Atricure Inc. Stock
A loss of -1.950% shows a downward development for Atricure Inc..
Atricure Inc. is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
With a target price of 46 € there is a hugely positive potential of 52.32% for Atricure Inc. compared to the current price of 30.2 €.
Pros and Cons of Atricure Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -1.950% | -1.307% | -11.696% | -51.290% | -11.176% | -51.290% | -37.860% |
| SI-BONE Inc | -0.750% | -5.036% | -24.571% | -20.482% | -21.893% | - | - |
| Orasure Tech | 0.880% | -0.862% | 8.491% | -39.474% | 11.650% | -53.815% | -80.342% |
| Lantheus Holdings Inc | -1.090% | -2.868% | -7.953% | -37.332% | -4.091% | -2.036% | - |
Comments
AtriCure (NASDAQ:ATRC) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure, Inc. (NASDAQ: ATRC) had its price target raised by analysts at Needham & Company LLC from $44.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at UBS Group AG from $60.00 to $58.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on
